Alpha 2.0
Login Register
» Authors » Stuart Oliver

Stuart Oliver

Explore the profile of Stuart Oliver including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 284
Followers 0
Related Specialties
Pharmacology
Oncology
Top 10 Co-Authors
Paul Martin
David Millson
Michael Gillen
Robert Smith
Clive Brealey
David Lau
Jessica Read
Sarah-Jane Kennedy
Tim Mant
Muhammad Baluom
Published In
Clin Ther
Clin Pharmacokinet
Cancer Chemother Pharmacol
Drugs R D
Clin Pharmacol Drug Dev
Affiliations
Soon will be listed here.
Recent Articles
1.
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects
Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, et al.
Clin Pharmacol Drug Dev . 2019 Mar; 8(6):790-801. PMID: 30861337
GSK3389404 is a liver-targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This first-in-human, randomized, double-blind, phase 1 study assessed the...
2.
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies
Martin P, Gillen M, Millson D, Oliver S, Brealey C, Surry D, et al.
Clin Pharmacol Drug Dev . 2016 May; 5(3):170-9. PMID: 27163495
Fostamatinib is a prodrug that undergoes gastrointestinal tract dephosphorylation to form the active metabolite, R406. Here we report its cytochrome P450-inducing potential. In vitro, R406 3 and 10 μM induced...
3.
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
Martin P, Gillen M, Millson D, Oliver S, Brealey C, Grossbard E, et al.
Drugs R D . 2016 Jan; 16(1):81-92. PMID: 26739683
Background: Fostamatinib (R788) is a spleen tyrosine kinase (SYK) inhibitor. The active metabolite of fostamatinib, R406, is primarily metabolized by CYP3A4. Objectives: The aim of this study was to characterize...
4.
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies
Martin P, Oliver S, Gillen M, Marbury T, Millson D
Clin Ther . 2015 Nov; 37(12):2823-36. PMID: 26519231
Purpose: Phase III trials of fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis have been completed. Herein, we report the effects of renal and hepatic...
5.
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies
Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, et al.
Clin Ther . 2015 Oct; 37(12):2811-22. PMID: 26514315
Purpose: Fostamatinib, a spleen tyrosine kinase inhibitor and prodrug of the active metabolite R406, is being developed as an anti-inflammatory drug for several indications for which polypharmacy is likely. Digoxin,...
6.
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine
Johansson S, Read J, Oliver S, Steinberg M, Li Y, Lisbon E, et al.
Clin Pharmacokinet . 2014 Aug; 53(9):837-47. PMID: 25117183
Background And Objective: Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment...
7.
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
Dennis M, Davies M, Oliver S, DSouza R, Pike L, Stockman P
Cancer Chemother Pharmacol . 2012 Aug; 70(3):461-9. PMID: 22864876
Purpose: Barasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies...
8.
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects
Martin P, Oliver S, Kennedy S, Partridge E, Hutchison M, Clarke D, et al.
Clin Ther . 2011 Dec; 34(1):221-37. PMID: 22206795
Background: Vandetanib is an orally available inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor and is rearranged during transfection tyrosine kinase activity. Development has included...
9.
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T
BMC Clin Pharmacol . 2011 Mar; 11:3. PMID: 21414193
Background: Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of prostate cancer. As zibotentan is eliminated by renal and metabolic routes, clearance may...
10.
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole
Martin P, Oliver S, Robertson J, Kennedy S, Read J, Duvauchelle T
Drugs R D . 2011 Mar; 11(1):37-51. PMID: 21410294
Background: Vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET), is a developmental oncology drug, that is in...